patients a discussion of 42 patients in the text needs clarification. In addition, we cannot follow the assumption that a prostate involved with prostate cancer and treated with local radiation therapy and androgen deprivation therapy can be regarded as a 'normal prostate'. Also, interpretation of the clinical state of patient 21 described in the legend of Fig. 7 as harbouring probably dedifferentiated prostate cancer because of positive pelvic nodes and a serum prostate-specific antigen (PSA) concentration of 0.01 ng/ml is confusing as this patient already had a Gleason score of 9 of his primary and bone as well as soft tissue metastases (Table 1) and therapy beyond prostatectomy is not discussed. Moreover, one of the two positive nodes in this patient is an inguinal node, a localization where positive nodes from PCa are very rare. Generally, a definition of assessment criteria of assumed prostate cancer deposits and verification by some reference standard in more than the six histologically controlled patients described would have been very welcome. Interestingly, the authors try to explain 68 Ga-PSMA inhibitor biodistribution with rather high tracer uptake in lacrimal and salivary glands, nasal mucosa, liver, spleen, bowel, kidneys and bladder in the context of known PSMA tissue expression. A very similar biodistribution to that described by the authors was observed in a series of seven patients, examined with the PSMA inhibitor MIP-1072
by Barrett et al. very recently [4] . Also in this study, lesions from PCa could be imaged with high contrast using single photon emission computed tomography (SPECT)/CT as the imaging technique [4] . Studying relapsing prostate cancer with another 68 Ga-PSMA inhibitor, 68 Ga-DOTA-DUPA-Pep (8,11-dibenzyl-2,7,10,13,22,27-hexaoxo-1-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraaza-cyclododecan-1-yl)-3,6,9,12,21,26,28-heptaazahentriacontane-25,29,31-tricarboxylic acid) we can confirm the very favourable imaging properties of PSMA targeting with urea-based inhibitors for showing metastatic disease with PET/CT (Fig. 1a) , but we observed a remarkably different biodistribution (Fig. 1b) to that described by Afshar-Oromieh et al. [5] . We found predominant tracer uptake in kidneys, urinary tract, blood pool and lesions from PCa (Fig. 1a) and only very faint uptake in salivary glands and also in gynaecomastia (Fig. 1b) . Interestingly, a current paper by Pomper's group using the 18 F-
F-fluorobenzyl-L-cysteine ( 18 F-DCFBC) described a strikingly similar biodistribution to that of 68 Ga-DOTA-DUPA-Pep [6] . Thus, PSMA addressing through urea-based inhibitors with appropriate radiolabelled peptides seems to provide a very promising approach for targeting various stages of PCa in patients; however, factors governing extraprostatic tissue distribution need further careful analysis and consideration.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. a b Ga-DOTA-DUPA-Pep PET shows uptake in kidneys, urinary tract and blood pool and faintly in salivary and lacrimal glands. There is no evidence of tumour deposits. Interestingly, also faint uptake is seen due to gynaecomastia (arrowheads). MIP PET as in a, 105 MBq 68 Ga-DOTA-DUPA-Pep
